Citi says buy the dip in Eli Lilly ahead of Alzheimer's drug launch
[ad_1]
The recent pullback in Eli Lilly's stock provides an attractive buying opportunity ahead of the pharmaceutical company's Alzheimer's drug launch, Citi said.
[ad_2]
[ad_1]
The recent pullback in Eli Lilly's stock provides an attractive buying opportunity ahead of the pharmaceutical company's Alzheimer's drug launch, Citi said.
[ad_2]